TheraCryf (LSE:TCF) Change In Receivables: £-0.13 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TheraCryf Change In Receivables?

TheraCryf LSE:TCF Change In Receivables is £-0.13 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's change in receivables for the quarter that ended in Sep. 2025 was £-0.00 Mil. It means TheraCryf's Accounts Receivable increased by £0.00 Mil from Mar. 2025 to Sep. 2025 .

TheraCryf's change in receivables for the fiscal year that ended in Mar. 2025 was £0.08 Mil. It means TheraCryf's Accounts Receivable declined by £0.08 Mil from Mar. 2024 to Mar. 2025 .

TheraCryf's Accounts Receivable for the quarter that ended in Sep. 2025 was £0.52 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. TheraCryf's liquidation value for the six months ended in Sep. 2025 was £2.07 Mil.

TheraCryf  (LSE:TCF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

TheraCryf's Days Sales Outstanding for the quarter that ended in Sep. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.515/0*91
=

2. In Ben Graham's calculation of liquidation value, TheraCryf's accounts receivable are only considered to be worth 75% of book value:

TheraCryf's liquidation value for the quarter that ended in Sep. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3.496-1.816+0.75 * 0.515+0.5 * 0
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Change In Receivables Related Terms

TheraCryf Change In Receivables Historical Data

* Premium members only.

The historical data trend for TheraCryf's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Change In Receivables Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 0.11 -0.09 -0.38 0.08

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 -0.01 0.21 -0.13 -0.00

TheraCryf Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of £-0.13 Mil mean?
TheraCryf (LSE:TCF) has a Change In Receivables of £-0.13 Mil as of Sep. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TheraCryf and its competitors.
Is TheraCryf's Change In Receivables too high?
TheraCryf's current Change In Receivables is £-0.13 Mil.
How does TheraCryf's Change In Receivables compare to VRTX and REGN?
TheraCryf's Change In Receivables of £-0.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for TheraCryf and its competitors. TheraCryf's current Change In Receivables is £-0.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Change In Receivables of £-0.13 Mil. The current Change In Receivables is £-0.13 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Change In Receivables is £-0.13 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.